The effects of brain and C-type natriuretic peptides on corticotropin- releasing factor in brain of rats

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The central corticotropin-releasing factor (CRF)-ergic system plays a critical role in anxiety and other behavioral stress responses. It has been shown that atrial (ANP), brain (BNP) and C-type (CNP) natriuretic peptides exert anxiolytic-like effects in behavioral studies. Our previous findings demonstrated that various doses of centrally administered ANP selectively altered the CRF content in different brain areas. In the present study, CRF immunoreactivity was determined in hypothalamic and extrahypothalamic brain regions after central injection of BNP or CNP in rats. A high dose (400 ng) of BNP significantly increased the CRF-like immunoreactivity (CRF-LI) in the hypothalamus and amygdala, while only a tendency towards an increase was found in the hippocampus. In the hypothalamus, the CRF-LI decreased after a high dose (400 ng) of CNP. The CRF-LI increased in the basal forebrain after a low dose (100 ng) of CNP. These results suggest that CRF may be involved in the mediation of some neuroendocrine and behavioral responses to BNP and CNP.

Original languageEnglish
Pages (from-to)2111-2117
Number of pages7
JournalLife Sciences
Volume60
Issue number23
DOIs
Publication statusPublished - May 2 1997

Fingerprint

C-Type Natriuretic Peptide
Brain Natriuretic Peptide
Corticotropin-Releasing Hormone
Rats
Brain
Atrial Natriuretic Factor
Hypothalamus
Natriuretic Peptides
Anti-Anxiety Agents
Amygdala
Hippocampus
Anxiety
Injections

Keywords

  • brain natriuretic peptide
  • C-type natriuretic peptide
  • CRF-like immunoreactivity
  • hypothalmus

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{cec58d96cc76444fa6fc66244b1e1ad5,
title = "The effects of brain and C-type natriuretic peptides on corticotropin- releasing factor in brain of rats",
abstract = "The central corticotropin-releasing factor (CRF)-ergic system plays a critical role in anxiety and other behavioral stress responses. It has been shown that atrial (ANP), brain (BNP) and C-type (CNP) natriuretic peptides exert anxiolytic-like effects in behavioral studies. Our previous findings demonstrated that various doses of centrally administered ANP selectively altered the CRF content in different brain areas. In the present study, CRF immunoreactivity was determined in hypothalamic and extrahypothalamic brain regions after central injection of BNP or CNP in rats. A high dose (400 ng) of BNP significantly increased the CRF-like immunoreactivity (CRF-LI) in the hypothalamus and amygdala, while only a tendency towards an increase was found in the hippocampus. In the hypothalamus, the CRF-LI decreased after a high dose (400 ng) of CNP. The CRF-LI increased in the basal forebrain after a low dose (100 ng) of CNP. These results suggest that CRF may be involved in the mediation of some neuroendocrine and behavioral responses to BNP and CNP.",
keywords = "brain natriuretic peptide, C-type natriuretic peptide, CRF-like immunoreactivity, hypothalmus",
author = "J. Gardi and {\'E}va B{\'i}r{\'o} and M. Vecserny{\'e}s and J. Julesz and T. Ny{\'a}ri and G. T{\'o}th and G. Telegdy",
year = "1997",
month = "5",
day = "2",
doi = "10.1016/S0024-3205(97)00198-7",
language = "English",
volume = "60",
pages = "2111--2117",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "23",

}

TY - JOUR

T1 - The effects of brain and C-type natriuretic peptides on corticotropin- releasing factor in brain of rats

AU - Gardi, J.

AU - Bíró, Éva

AU - Vecsernyés, M.

AU - Julesz, J.

AU - Nyári, T.

AU - Tóth, G.

AU - Telegdy, G.

PY - 1997/5/2

Y1 - 1997/5/2

N2 - The central corticotropin-releasing factor (CRF)-ergic system plays a critical role in anxiety and other behavioral stress responses. It has been shown that atrial (ANP), brain (BNP) and C-type (CNP) natriuretic peptides exert anxiolytic-like effects in behavioral studies. Our previous findings demonstrated that various doses of centrally administered ANP selectively altered the CRF content in different brain areas. In the present study, CRF immunoreactivity was determined in hypothalamic and extrahypothalamic brain regions after central injection of BNP or CNP in rats. A high dose (400 ng) of BNP significantly increased the CRF-like immunoreactivity (CRF-LI) in the hypothalamus and amygdala, while only a tendency towards an increase was found in the hippocampus. In the hypothalamus, the CRF-LI decreased after a high dose (400 ng) of CNP. The CRF-LI increased in the basal forebrain after a low dose (100 ng) of CNP. These results suggest that CRF may be involved in the mediation of some neuroendocrine and behavioral responses to BNP and CNP.

AB - The central corticotropin-releasing factor (CRF)-ergic system plays a critical role in anxiety and other behavioral stress responses. It has been shown that atrial (ANP), brain (BNP) and C-type (CNP) natriuretic peptides exert anxiolytic-like effects in behavioral studies. Our previous findings demonstrated that various doses of centrally administered ANP selectively altered the CRF content in different brain areas. In the present study, CRF immunoreactivity was determined in hypothalamic and extrahypothalamic brain regions after central injection of BNP or CNP in rats. A high dose (400 ng) of BNP significantly increased the CRF-like immunoreactivity (CRF-LI) in the hypothalamus and amygdala, while only a tendency towards an increase was found in the hippocampus. In the hypothalamus, the CRF-LI decreased after a high dose (400 ng) of CNP. The CRF-LI increased in the basal forebrain after a low dose (100 ng) of CNP. These results suggest that CRF may be involved in the mediation of some neuroendocrine and behavioral responses to BNP and CNP.

KW - brain natriuretic peptide

KW - C-type natriuretic peptide

KW - CRF-like immunoreactivity

KW - hypothalmus

UR - http://www.scopus.com/inward/record.url?scp=0343488664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343488664&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(97)00198-7

DO - 10.1016/S0024-3205(97)00198-7

M3 - Article

C2 - 9180365

AN - SCOPUS:0343488664

VL - 60

SP - 2111

EP - 2117

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 23

ER -